Magic mushrooms can lead to long-term improvements in depression, study finds
Marijuana Stocks, Finance, & InvestingUncategorized April 16, 2022 MJ Shareholders
Magic mushroom’s drug psilocybin can lead to long-term improvements in depression symptom severity, a small study has found.
The study, conducted by the Imperial College of London, looked at brain scans of 60 participants and combines two trials where psilocybin was administered.
In the first trial, everyone received psilocybin, and in the second one, some received psilocybin and others took a different kind of antidepressant. The peer reviewed research was published on Monday in Nature Medicine.
“In both trials, the antidepressant response to psilocybin was rapid, sustained and correlated with decreases in fMRI brain network modularity, implying that psilocybin’s antidepressant action may depend on a global increase in brain network integration,” the study reads.
MJ Shareholders
MJShareholders.com is the largest dedicated financial network and leading corporate communications firm serving the legal cannabis industry. Our network aims to connect public marijuana companies with these focused cannabis audiences across the US and Canada that are critical for growth: Short and long term cannabis investors Active funding sources Mainstream media Business leaders Cannabis consumers
